The role of megestrol acetate as an alternative to conventional hormone replacement therapy

References

• Campbell S, Whitehead M. Oestrogen therapy and the post-menopausal syndrome. Clin Obstet Gynecol 1977; 4: 31–47
   Google Scholar
• Coope J, Thomson J. Effect of ‘natural’ oestrogens on menopausal symptoms and blood clotting. Br Med J 1975; 4: 139–43
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Colditz G A. Oestrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart D M, Aitken JM, et al. Long-term prevention of post-menopausal osteoporosis by oestrogen: evidence for increased bone mass after delayed onset of oestrogen treatment. Lancet 1976; 1: 1038–41
   PubMed Web of Science ®Google Scholar
• Hillard T C, Whitcroft S J, Marsh M S. Long term effects of transdermal and oral hormone replacement therapy in post-menopausal bone loss. Osteoporosis Int 1994; 4: 341–8
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Hart D M, Lindsay R. Long-term effect of oestrogen replacement therapy on bone mass as measured by dual photon absorptiometry. Br Med J 1987; 294: 1261–2
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59
   PubMed Web of Science ®Google Scholar
• Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1 year double-blind, placebo controlled study. Thromb Haemost 1996; 75: 476–80
   PubMed Web of Science ®Google Scholar
• Jick H, Derby L E, Myers M W, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey M P, Hawkins M M, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80
   PubMed Web of Science ®Google Scholar
• Schiff I, Tulchinksy D, Cramer D, et al. Oral medroxyprogesterone acetate in the treatment of postmenopausal symptoms. J Am Med Assoc 1980; 244: 1443–5
   PubMed Web of Science ®Google Scholar
• Paterson M EL. A randomised double-blind cross over trial into the effects of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982; 89: 464–7
   PubMedGoogle Scholar
• Farish E, Fletcher C D, Hart D M, et al. Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 1986; 159: 147–51
   PubMed Web of Science ®Google Scholar
• Trémollieres F, Pouilles J-M, Ribot C. Effect of long term administration of progestogen on postmenopausal bone loss: result of a two-year controlled randomized study. Clin Endocrinol 1993; 38: 627–31
   PubMed Web of Science ®Google Scholar
• Trémollieres F A, Pouilles J-M, Ribot C A. A prospective two-year study of progestin given alone in postmenopausal women: effect on lipid and metabolic parameters. Am J Obstet Gynecol 1995; 173: 85–9
   PubMed Web of Science ®Google Scholar
• Schlaff W D, Dugoff L, Damewood M D, et al. Megestrol acetate for treatment of endometriosis. Obstet Gynecol 1990; 75: 646–8
   PubMed Web of Science ®Google Scholar
• Loprinzi C L, Michalak J C, Quella R N, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–52
   PubMed Web of Science ®Google Scholar
• Quella S K, Loprinzi C L, Sloan J A, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82: 1784–8
   PubMed Web of Science ®Google Scholar
• Erlik Y, Meldrum D R, Lagasse L D, et al. Effect of megestrol acetate on flushing, and bone metabolism in postmenopausal women. Maturitas 1981; 3: 167–72
   PubMed Web of Science ®Google Scholar
• Makkonen M, Saarikoski S, Penttilä I. Effects of oestradiol valerate plus two different progestogens on serum lipids during post-menopausal replacement therapy. Maturitas 1991; 14: 43–8
   PubMed Web of Science ®Google Scholar
• Greene J G. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31
   PubMed Web of Science ®Google Scholar
• Fletcher C D, Barnes J F, Farish E. A rapid semi-micro method for the separation of lipoprotein fractions that uses a benchtop ultracentrifuge. Clin Chim Acta 1994; 226: 95–9
   PubMed Web of Science ®Google Scholar
• Farish E, Barnes J F, Rolton H, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1995; 20: 215–19
   Web of Science ®Google Scholar
• Derman R J, Dawood M Y, Stone S. Quality of life during sequential hormone replacement therapy - a placebo controlled study. Int J Fertil 1995; 40: 73–8
   Google Scholar
• Holst J, Bäckström T, von Schoultz B. Progestogen addition during oestrogen replacement therapy - effects on vasomotor symptoms and mood. Maturitas 1989; 11: 13–20
   PubMed Web of Science ®Google Scholar
• Sherwin B B. The impact of different doses of estrogen and progestin on mood and sexual behaviour in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 336–43
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Burrows G D, Hyman G J, et al. Hormone therapy and affect. Maturitas 1979; 1: 247–59
   PubMed Web of Science ®Google Scholar
• Prior J C, Alojado R N, McKay D W, et al. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. Obstet Gynecol 1994; 83: 24–8
   PubMed Web of Science ®Google Scholar
• Stevenson J C. Are changes in lipoproteins during HRT important?. Br J Obstet Gynaecol 1996; 103: 39–44
   PubMedGoogle Scholar
• Scanu A M. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. J Am Med Assoc 1992; 267: 3326–9
   PubMed Web of Science ®Google Scholar
• Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 259–62
   PubMedGoogle Scholar
• Farish E, Rolton H A, Barnes J F, et al. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. Br Med J 1991; 303: 694
   PubMed Web of Science ®Google Scholar
• Ylöstalo P, Kauppila A, Kivinen S, et al. Endocrine and metabolic effects of low dose estrogen-progestin treatment in climacteric women. Obstet Gynecol 1983; 62: 682–6
   PubMed Web of Science ®Google Scholar
• Sporrong T, Hellgren M, Samsioe G, et al. Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women. Obstet Gynecol 1989; 73: 754–8
   PubMed Web of Science ®Google Scholar
• Miller N E, Hammett F, Sultissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein sub-fractions and apolipoproteins. Br Med J 1981; 282: 1741–4
   PubMed Web of Science ®Google Scholar
• Lapidus L, Bengtsson C, Lindquist O, et al. Triglycerides - main lipid risk factor for cardiovascular disease in women?. Acta Med Scand 1985; 217: 481–9
   PubMed Web of Science ®Google Scholar
• Meade T W, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533–7
   PubMed Web of Science ®Google Scholar
• Kannel W B, Wolf P A, Castelli W P, et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. J Am Med Assoc 1987; 258: 1183–6
   PubMed Web of Science ®Google Scholar
• Meade T W, Haines A P, Imeson J D, et al. Menopausal status and haemostatic variables. Lancet 1983; 1: 22–4
   PubMed Web of Science ®Google Scholar
• Gilabert J, Estellés A, Cano A, et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849–54
   PubMed Web of Science ®Google Scholar
• Glueck H I, Glueck C J. Clotting mechanisms in patients with hypertriglyceridemia during therapy with anabolic or progestational drugs. Thromb Diathes Haemorrh 1973; 29: 499–509
   PubMedGoogle Scholar
• Lorrain J, Harel P. Effects of certain contraceptive hormones on blood coagulation. Fertil Steril 1972; 23: 422–7
   PubMed Web of Science ®Google Scholar
• Wodzicki A M, Coopland A T. Chlormadinone acetate and its effect on the hemostatic mechanism. Can Med Assoc J 1972; 107: 38–41
   PubMed Web of Science ®Google Scholar
• Lira P, Rivera L, Diaz S, et al. Study of blood coagulation in women treated with megestrol acetate implants. Contraception 1991; 44: 639–48
   PubMedGoogle Scholar
• Sporrong T, Mattsson L-Å, Samsioe G, et al. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990; 97: 939–44
   PubMedGoogle Scholar
• Nabulsi A A, Folsom A R, White A, et al. Association of hormone replacement therapy with the various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75
   PubMed Web of Science ®Google Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24: 1–19
   PubMed Web of Science ®Google Scholar
• Winkler U H. Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseological findings. Fibrinolysis 1992; 6((Suppl 3))5–10
   Google Scholar
• Abdalla H I, Hart D M, Lindsay R, et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66: 789–92
   PubMed Web of Science ®Google Scholar
• Gallagher J C, Kable W T, Goldgar D. Effect of progestin therapy on cortical and trabecular bone; comparison with oestrogen. Am J Med 1991; 90: 171–8
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Hassager C, Christiansen C. Postmenopausal bone remodelling and hormone replacement. Climacteric 1998; 1: 72–9
   PubMedGoogle Scholar